SourceBio International on a roll with COVID-19 testing opportunity

0
146
  • SourceBio’s COVID-19 travel PCR testing service ranked top by Which?
  • SourceBio International ‘uniquely positioned to help NHS reduce backlog as a partner’
covid test

Quick facts: SourceBio International PLC

Follow

View company profile

SourceBio International PLC is a leading international provider of integrated state-of-the-art laboratory services and products with clients in the healthcare, clinical, life science research and biopharma industries, with a focus on improving patient diagnosis, management and care.

Group revenues are derived from four core businesses areas: Healthcare Diagnostics, Genomics, Stability Storage and Infectious Disease Testing.

22 Oct 2021

The PCR Coronavirus (COVID-19) testing service from () was top of a short-list of four of “the best cheap day two Covid tests for travel” by the Which? consumer organisation.

Which?, the UK’s ‘consumer champion’, looked at the 50 companies suggested on the gov.uk website as providers of day-two PCR tests, but whittled this down to only those that charged no more than GBP60 and which offered home delivery and easy accessible Royal Mail boxes.

This resulted in a short-list of four firms, which were all mystery-shopped 13 times, checking whether test kits and results arrived on time.

In the article on the Which? website, SourceBio’s service was deemed “the most reliable choice, although more expensive than others we checked”, with “excellent results” in the mystery shop, all tests and results arriving on time and the article also noting that the laboratory is fully accredited.

Read more

28 Sep 2021

SourceBio International PLC (AIM:SBI, FRA:6J8) said trading in the third quarter has been strong driven by peak levels of PCR testing, lifting revenues, earnings and cash generation.

However, the lab services provider noted that changes in the Coronavirus (COVID-19) travel guidelines announced earlier this month are expected to reduce the throughput by 70% compared to the third quarter, hitting revenue.

Read more

20 Sep 2021

SourceBio International PLC (AIM:SBI) said the planned changes to England’s international travel rules and COVID-19 testing requirements are likely to have an impact on expected revenues this year.

Full-year revenues and adjusted EBITDA are still expected to show dramatic growth compared to the previous year, however, the changes to travel PCR testing are expected to impact on the level of this expected material growth, it said in a statement.

Read more

25 Oct 2021

() (AIM:SBI, ) executive chairman Jay LeCoque joined Proactive’s Katie Pilbeam to talk about their role in the COVID-19 pandemic and to tackle the huge treatment backlog.

The UK will set aside a further 5.4 billion pounds over the next six months to help its National Health Service cover additional costs and LeCoque says they are set up to help immediately.

The firm is a leading international provider of integrated state-of-the-art laboratory services and products with clients in the healthcare, clinical, life science research and biopharma industries, with a focus on improving patient diagnosis, management and care.

15 Feb 2021

SourceBio International (SBI) has made a huge impact on its return to public markets. It reported a 139% rise in fiscal 2020 (FY20) reported revenues to GBP50.7mln from GBP21.2mln and underlying earnings (EBITDA) of GBP14mln, vs GBP3mln in FY19. Growth was driven largely on its rapid mobilisation of resources to create a new fourth division, infectious disease testing services.

Read full report



Download Research

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is…

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash…

FOR OUR FULL DISCLAIMER CLICK HERE

SourceBio International ‘uniquely positioned to help NHS reduce backlog as a…

SourceBio International PLC (AIM:SBI) (AIM:SBI, FRA:6J8) executive chairman Jay LeCoque joined Proactive’s Katie Pilbeam to talk about their role in the COVID-19 pandemic and to tackle the huge treatment backlog.

The UK will set aside a further 5.4 billion pounds over the next six months to…

12 hours, 11 minutes ago

2 min read

LEAVE A REPLY

Please enter your comment!
Please enter your name here